CARM
- Carisma Therapeutics, Inc.
()
Overview
Company Summary
Carisma Therapeutics, Inc. is a biotechnology company that specializes in developing novel CAR (Chimeric Antigen Receptor) macrophage immunotherapies for the treatment of cancer. CAR macrophage immunotherapies are a type of cellular therapy that harnesses the power of the body's immune system to recognize and eliminate cancer cells.
Carisma's approach is unique because it utilizes macrophages, which are a type of immune cell responsible for identifying and engulfing foreign substances and abnormal cells in the body. By genetically engineering these macrophages with CAR technology, the company aims to enhance their ability to specifically target and destroy cancer cells.
The CAR technology used by Carisma enables macrophages to recognize and bind to specific cancer cell surface markers. Once bound, the macrophages become activated and can release toxic substances to destroy the cancer cells. This approach has the potential to provide a more targeted and potentially less toxic treatment option for patients with cancer.
Carisma is focused on developing CAR macrophage immunotherapies for a range of solid tumors and hematological malignancies. The company is actively conducting preclinical and clinical studies to evaluate the safety and efficacy of their therapies, with the goal of eventually bringing them to market and improving outcomes for patients with cancer.
In summary, Carisma Therapeutics is dedicated to developing CAR macrophage immunotherapies that utilize genetically modified macrophages to enhance the body's immune response against cancer cells. Their innovative approach holds promise for the development of targeted and effective therapies for various types of cancer.